ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jaffar, Z.
Right arrow Articles by Costello, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jaffar, Z.
Right arrow Articles by Costello, J
Eur Respir J 1996; 9: 456-462
Copyright © ERS Journals Ltd 1996


Clinical Trial

Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics

ZH Jaffar, P Sullivan, C Page, and J Costello

Theophylline has been shown by several investigators to attenuate the late asthmatic response (LAR) to inhaled allergen, suggesting that it has anti-inflammatory or immunomodulatory properties. We have, therefore, undertaken a double-blind, placebo-controlled study to examine the effects of low-dose theophylline on bronchoalveolar lavage (BAL) and blood T-lymphocyte profile and activation in asthmatics following antigen challenge and the development of a LAR. Peripheral blood and BAL samples were obtained from 17 subjects with mild atopic asthma before and after 6 weeks of treatment with either oral theophylline or placebo. The mean serum theophylline concentration achieved was 6.6 micrograms.mL-1, which is below the currently accepted therapeutic range. Following theophylline therapy, there was a significant decrease in the number of BAL lymphocytes compared to placebo. On flow cytometric analysis of BAL cells, a significant loss of CD3+ T-lymphocytes, comprising both CD4+ and CD8+ subsets, was demonstrated. Moreover, there was a decrease in the number of BAL CD4+ T-cells expressing the activation marker very late activation antigen-1 (VLA-1), and an apparent reduction in human leucocyte antigen-DR (HLA-DR). Correspondingly, this was accompanied in the blood by an elevation in the proportion of activated CD4+ T-lymphocytes, in particular those expressing HLA-DR. These findings provide further evidence that theophylline has an anti-inflammatory action in asthma.


This article has been cited by other articles:


Home page
Eur Respir JHome page
M. Spears, I. Donnelly, L. Jolly, M. Brannigan, K. Ito, C. McSharry, J. Lafferty, R. Chaudhuri, G. Braganza, I. M. Adcock, et al.
Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study
Eur. Respir. J., May 1, 2009; 33(5): 1010 - 1017.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
P. J. Barnes
Theophylline: New Perspectives for an Old Drug
Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 813 - 818.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Ito, S. Lim, G. Caramori, B. Cosio, K. F. Chung, I. M. Adcock, and P. J. Barnes
A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression
PNAS, June 25, 2002; 99(13): 8921 - 8926.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
B. J. Lipworth, F. Chung, P. Barnes, and S. Lim
EFFECTS OF THEOPHYLLINE ON AIRWAY EOSINOPHILS
Am. J. Respir. Crit. Care Med., March 15, 2002; 165(6): 845 - 845.
[Full Text] [PDF]


Home page
CVIHome page
R. J. Harbeck

Clin. Vaccine Immunol., May 1, 1998; 5(3): 271 - 277.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the European Respiratory Society.